Evidence map›Paper›PMID 28781658›Full record

ArticleOncology letters2017

Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report.

Fabiana Pani, Elisabetta Macerola, Fulvio Basolo, Francesco Boi, Mario Scartozzi, Stefano Mariotti

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fabiana PaniEndocrinology Unit, Department of Medical Sciences 'M. Aresu', University of Cagliari and University Hospital of Cagliari, I-09042 Cagliari, Italy.
Elisabetta MacerolaDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa and University Hospital of Santa Chiara, Pisa I-56126, Italy.
Fulvio BasoloDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa and University Hospital of Santa Chiara, Pisa I-56126, Italy.
Francesco BoiEndocrinology Unit, Department of Medical Sciences 'M. Aresu', University of Cagliari and University Hospital of Cagliari, I-09042 Cagliari, Italy.
Mario ScartozziMedical Oncology Unit, Department of Medical Sciences 'M. Aresu', University Hospital of Cagliari and University of Cagliari, I-09042 Cagliari, Italy.
Stefano MariottiEndocrinology Unit, Department of Medical Sciences 'M. Aresu', University of Cagliari and University Hospital of Cagliari, I-09042 Cagliari, Italy.
University of Cagliari · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of advanced differentiated thyroid carcinoma (DTC). Resistance to sorafenib may appear under treatment and may be associated with increased aggressiveness of the neoplasia. The present study reports the case of a 65-year-old male who underwent total thyroidectomy for a follicular thyroid carcinoma, Hürthle cell variant, in February 2005. Until January 2010, the patient received four consecutive

Indexed as

metastasesmolecular biologyoncogenessorafenibthyroid cancer

Identifiers

PMID28781658
PMCPMC5530175
OpenAlexW2626146225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.